TC
VNDA icon

TradeLink Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

TradeLink Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-9,000
Closed -$146K – 388
2014
Q1 		$146K Buy
+9,000
New +$128K 0.21% 158

Other funds holding VNDA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SCA
Signpost Capital Advisors New York $34.2M AUM 5.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TradeLink Capital's VNDA Position: Q2 2014 in Review

TradeLink Capital sold out of Vanda Pharmaceuticals (VNDA) in Q2 2014, closing a stake of 9,000 shares — an estimated $146K sold.

TradeLink Capital first reported a position in VNDA in Q1 2014 and held it in 1 quarter. The position peaked at $146K in Q1 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q2 2014.

  • TradeLink Capital reported no remaining Vanda Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • TradeLink Capital sold 9,000 Vanda Pharmaceuticals shares in Q2 2014, an estimated $146K.
  • TradeLink Capital first reported a position in Vanda Pharmaceuticals in Q1 2014 and held it in 1 quarter.
  • TradeLink Capital's Vanda Pharmaceuticals position peaked at $146K in Q1 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2014.

Based on TradeLink Capital's 13F filing for Q2 2014, filed 31 Jul 2014.